Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer

Journal of Clinical Oncology

Volumn 31, Issue 32, 2013, Pages 4092-4098

  Vitolins, Mara Z ^a   Griffin, Leah ^a   Tomlinson, W Vic ^d   Vuky, Jacqueline ^e   Adams, Paul T ^f   Moose, Dawn ^b   Frizzell, Bart ^a   Lesser, Glenn J ^a   Naughton, Michelle ^a   Radford, James E ^c   Shaw, Edward G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b Novant Health   (United States)

^c Hendersonville Hematology Oncology   (United States)

^d ANMED HEALTH   (United States)

^e VIRGINIA MASON MEDICAL CENTER   (United States)

^f NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MILK PROTEIN; PLACEBO; SOYBEAN PROTEIN; VENLAFAXINE; ANTIANDROGEN; CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CAUCASIAN; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; CLINICAL TRIAL; HOT FLASHES; MIDDLE AGED; PROSTATIC NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; HOT FLASHES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SEROTONIN UPTAKE INHIBITORS; SOYBEAN PROTEINS;

EID: 84891712916     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.1432     Document Type: Article

References (22)

1. Schow DA, Renfer LG, Rozanski TA, et al: Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 91:855-857, 1998
2. Charig CR, Rundle JS: Flushing: Long-term side effect of orchiectomy in treatment of prostatic carcinoma. Urology 33:175-178, 1989
3. Quella S, Loprinzi CL, Dose AM: A qualitative approach to defining "hot flashes" in men. Urol Nurs 14:155-158, 1994
4. Shanafelt TD, Barton DL, Adjei AA, et al: Pathophysiology and treatment of hot flashes. Mayo Clin Proc 77:1207-1218, 2002
5. Roth AJ, Scher HI: Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology 7:129-132, 1998
6. Buijs C, Mom CH, Willemse PH, et al: Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: A double-blind, randomized cross-over study. Breast Cancer Res Treat 115:573-580, 2009
7. Quella SK, Loprinzi CL, Sloan J, et al: Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 162:98-102, 1999
8. Irani J, Salomon L, Oba R, et al: Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: A doubleblind, randomised trial. Lancet Oncol 11:147-154, 2010
9. Sharma P, Wisniewski A, Braga-Basaria M, et al: Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. J Urol 182:2265-2272, 2009
10. Messina M, Hughes C: Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Med Food 6:1-11, 2003
11. Albertazzi P, Pansini F, Bonaccorsi G, et al: The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 91:6-11, 1998
12. Burke GL, Legault C, Anthony M, et al: Soy protein and isoflavone effects on vasomotor symptoms in peri- and postmenopausal women: The Soy Estrogen Alternative Study. Menopause 10:147-153, 2003
13. Murkies AL, Lombard C, Strauss BJ, et al: Dietary flour supplementation decreases post-menopausal hot flushes: Effect of soy and wheat. Maturitas 21:189-195, 1995
14. Setchell KD: Phytoestrogens: The biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68:1333S-1346S, 1998
15. Knight DC, Eden JA: A review of the clinical effects of phytoestrogens. Obstet Gynecol 87:897-904, 1996
16. Van Patten CL, Olivotto IA, Chambers GK, et al: Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: A randomized, controlled clinical trial. J Clin Oncol 15:1449-1455, 2002
17. Bolaños R, Del Castillo A, Francia J: Soy isoflavones versus placebo in the treatment of climacteric vasomotor symptoms: Systematic review and meta-analysis. Menopause 17:660-666, 2010
18. Lethaby AE, Brown J, Marjoribanks J, et al: Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 4:CD001395, 2007
19. Esper P, Mo F, Chodak G, et al: Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 50:920-928, 1997
20. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
21. Loprinzi CL, Kugler JW, Sloan JA, et al: Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 356:2059-2063, 2000
22. Liu LX, Chen WF, Xie JX, et al: Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Neurosci Res 60:156-161, 2008